Type II Diabetes
Conditions
Keywords
CKD-378
Brief summary
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
Detailed description
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety after Oral Administration of CKD-378 and Co-administration of D745, D150 in Healthy Adults
Interventions
DRUGCKD-378, QD, PO Drug: D745, D150, QD, PO
Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult aged between 19 to 55 at screening 2. Weight ≥ 50kg(man) or 50kg(woman) 3. Body mass index (BMI) of 18.5 to 27.0kg/m2 4. If female, one of following conditions. Menopause (no menstruation more than 2 years) or surgically sterilized. 5. Those who agree to contraception from the first IP dosing day till 28 days after the last dosing day and decide not to provide sperm during the participation of clinical trial 6. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial
Exclusion criteria
1. Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Haemato-oncology disorder, Cardiovascular disorder or Psychical disorder. 2. Those who are vulnerable to dehydration due to lack of ability in oral intake or have dehydration. 3. Those who had medical examination requiring radioactive iodine contrast material injected through IV 48 hours prior to first IP administration. 4. Those who have significant disease or medical history of urinary infection. 5. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 6. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption. 7. Those who have hypersensitivity to the main constituents or components of the investigational drug such as empagliflozin, metformin. 8. Those who have tested inappropriate in screening test 28 days prior to IP administration. * AST, ALT \> 1.5 times higher than upper normal level * eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) \< 60 mL/min/1.73m2 * Positive or Reactive test result of Hepatitis B & C, HIV, RPR * Under 5 min resting condition, systolic blood pressure \>150 mmHg or or \<90 mmHg, diastolic blood pressure \>100 mmHg or \<50 mmHg. 9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test. 10. Woman who are pregnant or breastfeeding 11. Those who exceed an alcohol, caffeine and cigarette consumption (caffeine\> 5 cups/day, alcohol\> 210g/week, smoking\> 10 cigarettes/day) and not able to stop on smoking, caffeine and alcohol 12. Those who have used following drugs that can interfere with the study or have impact on safety of the subject. * ETC, herbal medicinal preparations within 14 days before the first dosing date * OTC, vitamins, health supplement within 7 days before the first dosing date * Depot injection or implantation within 30 days before the first dosing date 13. Those who received investigational products or participated in bioequivalence test within 180 days before the first administration of clinical trial drugs 14. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days 15. Those who have received blood transfusion in 30 days 16. Those who are deemed insufficient to participate in clinical study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. AUCt of CKD-378: Area under the concentration-time curve time zero to time | Pre-dose(0 hour) to 48 hours |
| 2. Cmax of CKD-378: Maximum plasma concentration of the drug | Pre-dose(0 hour) to 48 hours |
Countries
South Korea
Outcome results
None listed